Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Capital Expenditures (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Capital Expenditures for 9 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 240.45% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11000.0 through Dec 2025, down 99.64% year-over-year, with the annual reading at $11000.0 for FY2025, 99.64% down from the prior year.
  • Capital Expenditures hit -$1.5 million in Q4 2025 for Sutro Biopharma, down from $1.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $13.2 million in Q4 2021 to a low of -$5.6 million in Q3 2021.
  • Historically, Capital Expenditures has averaged $1.5 million across 5 years, with a median of $1.1 million in 2024.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 2359.44% in 2021 and later plummeted 1098.96% in 2025.
  • Year by year, Capital Expenditures stood at $13.2 million in 2021, then crashed by 74.41% to $3.4 million in 2022, then plummeted by 57.2% to $1.4 million in 2023, then dropped by 25.88% to $1.1 million in 2024, then crashed by 240.45% to -$1.5 million in 2025.
  • Business Quant data shows Capital Expenditures for STRO at -$1.5 million in Q4 2025, $1.5 million in Q3 2025, and -$1.2 million in Q2 2025.